Dengue FeverNCT06877039
Characteristics of Clinical Laboratory Indicators in Patients with Dengue Fever
An observational study of Dengue Fever, run by Foshan Hospital of Traditional Chinese Medicine at 1 site in China.
Trial summary
The objective of this observational study was to understand the changes in laboratory indicators and clinical manifestations of dengue patients at various ages, and to provide new ideas for the treatment and prevention of dengue. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Dengue Fever
- What is being tested?
- Observational studies did not involve any interventions
- How many people
- 500 participants
- Where
- 1 siteChina
- Study dates
- 1 Aug 2024to 1 Dec 2024
- How long will I take part?
- 2 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The subjects in this study were dengue fever patients.
Who may be able to join
- Meet the clinical diagnostic criteria for dengue fever, with blood indicators showing that the dengue antigen is positive.
- No age limit for inclusion.
- Voluntarily agree to participate in the study and sign the informed consent.
- Complete clinical data available, including symptoms and laboratory tests, to support subsequent analysis.
Who cannot join
- Incomplete or unavailable clinical data. Patients will be excluded if sufficient laboratory data and symptoms cannot be collected.
- Unable to understand or unwilling to sign the informed consent for any reason.
Trial locations and contacts
1 site in 1 country.
China1 site
Foshan Hospital of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine, Foshan, 528051, Guangdong, China.
Foshan, Guangdong, 528000
About this study
Official title: Observational Study on the Characteristics of Clinical Laboratory Indicators in Patients with Dengue Fever
The objective of this observational study was to understand the changes in laboratory indicators and clinical manifestations of dengue patients at various ages, and to provide new ideas for the treatment and prevention of dengue. The main questions it aims to answer are: 1 What are the key abnormal items in blood routine indicators of dengue patients? 2 Does dengue affect liver function in patients? Will there be liver damage? And when? 3. What are the specific clinical manifestations of dengue patients?
- Conditions
- Dengue Fever
- Being tested
- Observational studies did not involve any interventions
- Medical subject headings
- Dengue
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Observational studies did not involve any interventionsOther
What is being measured
The primary outcome is the main question the study is designed to answer.
WBC
WBC (White Blood Cell count), unit: cells/µL. All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.
Measured: From January 2024 to December 2024
HGB (Hemoglobin)
HGB (Hemoglobin), unit: g/dL; All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.
Measured: From January 2024 to December 2024
PLT (Platelet count)
PLT (Platelet count), unit: cells/µL; All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.
Measured: From January 2024 to December 2024
ANC (Absolute Neutrophil Count)
ANC (Absolute Neutrophil Count), unit: cells/µL. All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.
Measured: From January 2024 to December 2024
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Mar 2025
- Study start1 Aug 2024
- Primary completion1 Dec 2024
- Study completion1 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dengue FeverStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 500 participants (actual)
- Target duration
- 2 Months
Sponsor and investigators
- Lead sponsor
- Foshan Hospital of Traditional Chinese Medicine
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Qilong Nie, Foshan Hospital of Traditional Chinese Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06877039
- Sponsor's protocol ID
- Foshan Hospital of Traditional
- Status last verified
- Mar 2025
- First submitted
- 27 Feb 2025
- Last updated
- 14 Mar 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Observational Study on the Characteristics of Clinical Laboratory Indicators in Patients with Dengue Fever
- ClinicalTrials.gov ID
- NCT06877039
- Acronym / sponsor ID
- Foshan Hospital of Traditional
- Conditions
- Dengue Fever
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 500 participants (actual)
- Lead sponsor
- Foshan Hospital of Traditional Chinese MedicineUniversity, hospital or other
- Study start
- 1 Aug 2024 (actual)
- Primary completion
- 1 Dec 2024 (actual)
- Study completion
- 1 Dec 2024 (actual)
- First posted
- 14 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this observational study was to understand the changes in laboratory indicators and clinical manifestations of dengue patients at various ages, and to provide new ideas for the treatment and prevention of dengue. The main questions it aims to answer are: 1 What are the key abnormal items in blood routine indicators of dengue patients? 2 Does dengue affect liver function in patients? Will there be liver damage? And when? 3. What are the specific clinical manifestations of dengue patients?
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 2 Months
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The subjects in this study were dengue fever patients.
Key inclusion criteria (4 listed)
Key exclusion criteria (2 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Observational studies did not involve any interventions | Other | – |
Primary outcome
WBC
Time frame: From January 2024 to December 2024
WBC (White Blood Cell count), unit: cells/µL. All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.
HGB (Hemoglobin)
Time frame: From January 2024 to December 2024
HGB (Hemoglobin), unit: g/dL; All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.
PLT (Platelet count)
Time frame: From January 2024 to December 2024
PLT (Platelet count), unit: cells/µL; All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.
ANC (Absolute Neutrophil Count)
Time frame: From January 2024 to December 2024
ANC (Absolute Neutrophil Count), unit: cells/µL. All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Mar 2025.
- Individual participant dataSharing planned: No
Related trials for Dengue Fever
Active, not recruitingPhase 3
A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1)
Healthy
RecruitingPhase 1
Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection
Healthy Volunteers, Dengue
Active, not recruiting
A Controlled Human Infection Model of Dengue
Dengue
RecruitingPhase 2/3
Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)
Dengue
RecruitingPhase 2
Adaptive Dengue Antiviral Platform Trial
Dengue, Antiviral Drugs
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Dengue Fever, run by Foshan Hospital of Traditional Chinese Medicine at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
WBC (time frame: From January 2024 to December 2024). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Mar 2025.